{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:34:37Z","timestamp":1791236077427,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1053\/j.seminoncol.2012.11.006","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T20:18:00Z","timestamp":1360009080000},"page":"56-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.1053","volume":"40","author":[{"given":"Christos","family":"Toumpanakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn E.","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2012.11.006_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib2","series-title":"WHO classification of tumours in the digestive system","first-page":"13","article-title":"Nomenclature and classification of neuroendocrine neoplasms of the digestive system","author":"Rindi","year":"2010"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1749-6632.1994.tb17262.x","article-title":"Expression of somatostatin receptors in normal, inflammed and neoplastic human gastrointestinal tissues","volume":"733","author":"Reubi","year":"1994","journal-title":"Ann NY Acad Sci"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","article-title":"Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors","volume":"440","author":"Papotti","year":"2002","journal-title":"Virchows Arch"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0016-5085(80)90586-7","article-title":"Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome","volume":"78","author":"Davis","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7326\/0003-4819-92-1-68","article-title":"Somatostatin inhibits diarrhea in the carcinoid syndrome","volume":"92","author":"Dharmsathaphorn","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/jcem-68-2-239","article-title":"Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men","volume":"68","author":"Sassolas","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem.87.1.8153","article-title":"Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly","volume":"87","author":"Caron","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jc.2011-2088","article-title":"Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy","volume":"97","author":"Bousquet","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2036.2000.00738.x","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR","volume":"14","author":"Tomassetti","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2009.04083.x","article-title":"Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR","volume":"30","author":"Toumpanakis","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.39.2.279","article-title":"Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients","volume":"39","author":"Ruszniewski","year":"1996","journal-title":"Gut"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)","volume":"34","author":"Khan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib23","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors","volume":"135","author":"Metz","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beem.2007.01.002","article-title":"Neuroendocrine tumors","volume":"21","author":"Pl\u00f6ckinger","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib27","first-page":"1259","article-title":"VIPomas: an update in diagnosis and management in a series of 11 patients","volume":"52","author":"Nikou","year":"2005","journal-title":"Hepatogastroenterology"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0950-3528(96)90019-6","article-title":"Gastrointestinal endocrine tumours","volume":"10","author":"Frankton","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000151222","article-title":"Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review","volume":"89","author":"Srirajaskanthan","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib30","first-page":"13","article-title":"Somatostatinoma\/inhibitory syndrome: a stastical evaluation of 173 reported cases as compared to other pancreatic endocrinomas","volume":"18","author":"Soga","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib31","first-page":"17","article-title":"A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome","volume":"78","author":"Lamberts","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0140-6736(84)90320-9","article-title":"Treatment of metastasising GRF-producing tumour with a long-acting somatostatin analogue","volume":"2","author":"von Werder","year":"1984","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/ERC-10-0175","article-title":"Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas","volume":"18","author":"Saveanu","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.11.006_bib34","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.dld.2003.11.018","article-title":"Somatostatin receptors: from basic science to clinical approach\u2014thyroid","volume":"36","author":"Zatelli","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2008.10.025","article-title":"Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients","volume":"65","author":"Srirajaskanthan","year":"2009","journal-title":"Lung Cancer"},{"issue":"Suppl 4","key":"10.1053\/j.seminoncol.2012.11.006_bib36","first-page":"iv1","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours","volume":"54","author":"Ramage","year":"2005","journal-title":"Gut"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.mce.2008.02.002","article-title":"Antitumor effects of somatostatin","volume":"286","author":"Pyronnet","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-9966-29-19","article-title":"Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives","volume":"29","author":"Appetecchia","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib39","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3748\/wjg.v16.i24.2963","article-title":"Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors","volume":"16","author":"Strosberg","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib40","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1008205415035","article-title":"High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects","volume":"8","author":"Eriksson","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib41","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1572-0241.1998.465_q.x","article-title":"Slow-release lanreotide treatment in endocrine gastrointestinal tumors","volume":"93","author":"Tomassetti","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib42","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors","volume":"23","author":"Ricci","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib44","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","article-title":"Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours","volume":"38","author":"Arnold","year":"1996","journal-title":"Gut"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib46","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors","volume":"77","author":"di Bartolomeo","year":"1996","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib47","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1008383132024","article-title":"Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide","volume":"11","author":"Ricci","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib48","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","article-title":"Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours","volume":"37","author":"Aparicio","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","article-title":"Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors","volume":"60","author":"Faiss","year":"1999","journal-title":"Digestion"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib50","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib51","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors","volume":"95","author":"Ducreux","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib52","first-page":"692","article-title":"The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel","volume":"34","author":"Bianchi","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib53","unstructured":"Massuti B, Alonso V, Marmol M, et al. Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive gastroenteropancreatic (GEP) and bronchopulmonary (BP) neuroendocrine tumors (NETs) who are not eligible to surgery or chemotherapy. Paper presented at: 16th European Multidisciplinary Cancer Congress; 2011 September 23\u201327; Stockholm, Sweden."},{"key":"10.1053\/j.seminoncol.2012.11.006_bib54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib55","doi-asserted-by":"crossref","unstructured":"Palazzo M, Lombard-Bohas C, Cadiot G, et al. Predictive factors of tumor control in patients with well-differentiated digestive endocrine carcinomas (WDEK) treated with lanreotide. Paper presented at: 19th United European Gastroenterology Week, 2011 October 22\u201326; Stockholm, Sweden.","DOI":"10.1016\/S0016-5085(11)63628-7"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib56","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib57","unstructured":"Blumberg J, Liyanage N, Caplin M. The CLARINET study\u2014assessing the effect of Lanreotide Autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Paper presented at: North American Neuroendocrine Tumor Symposium, 2011, October 20\u201322; Minneapolis, MN."},{"key":"10.1053\/j.seminoncol.2012.11.006_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","author":"Welin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib60","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"K\u00f6lby","year":"2003","journal-title":"Br J Surg"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib62","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib63","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib65","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib66","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib67","unstructured":"Valle J, Faivre S, Raoul JL, et al. Phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET): impact of somatostatin analogue (SSA) treatment on progression-free survival (PFS). Paper presented at: European Society for Medical Oncology, 2010, 8\u201312 October; Milan, Italy."},{"key":"10.1053\/j.seminoncol.2012.11.006_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000335595","article-title":"ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms","volume":"95","author":"Delle Fave","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib69","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM200008243430805","article-title":"Treatment of type II gastric carcinoid tumors with somatostatin analogues","volume":"343","author":"Tomassetti","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib70","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/00365520410005225","article-title":"Treatment of ECL cell carcinoids with octreotide LAR","volume":"39","author":"Fykse","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1677\/ERC-07-0251","article-title":"Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs","volume":"15","author":"Campana","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib72","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/EJE-08-0420","article-title":"Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours","volume":"159","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib73","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2010.539255","article-title":"Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids","volume":"46","author":"Jianu","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib74","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00268-011-1137-0","article-title":"Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor","volume":"35","author":"Zhang","year":"2011","journal-title":"World J Surg"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.regpep.2007.04.002","article-title":"A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation","volume":"143","author":"Kidd","year":"2007","journal-title":"Regul Pept"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib76","doi-asserted-by":"crossref","unstructured":"Kvols L, Wiedenmann B, Oberg K, et al. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. Paper presented at: American Society of Clinical Oncology GI Cancers Symposium 2006, 18\u201320 June; Atlanta, GA.","DOI":"10.1200\/jco.2006.24.18_suppl.4082"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib77","first-page":"140","article-title":"Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas","volume":"86","author":"Saveanu","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib78","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0006-2952(99)00010-6","article-title":"Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5","volume":"57","author":"Zambre","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib79","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1055\/s-0031-1287769","article-title":"Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors","volume":"43","author":"Culler","year":"2011","journal-title":"Horm Metab Res"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib80","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1677\/JOE-10-0342","article-title":"Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines","volume":"207","author":"Arvigo","year":"2010","journal-title":"J Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib81","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1677\/ERC-07-0271","article-title":"Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human nonfunctioning pituitary adenomas: a multi-center study","volume":"15","author":"Florio","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib82","unstructured":"Lesage C, Seymour C, Urbanavicious V, Beckers A, Kazanavicious G, Colao A. A phase II exploratory study of BIM23A760 in acromegalic patients: preliminary results of safety and efficacy after a single-dose administration. Paper presented at: 91st Annual Meeting of the Endocrine Society, 2009, 10\u201313 June; Washington, DC."},{"key":"10.1053\/j.seminoncol.2012.11.006_bib83","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1530\/eje.1.02307","article-title":"The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies","volume":"155","author":"O'Toole","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib84","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib85","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2967\/jnumed.111.088922","article-title":"First clinical evidence that imaging with somatostatin receptor antagonists is feasible","volume":"52","author":"Wild","year":"2011","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.11.006_bib86","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1530\/ERC-10-0282","article-title":"Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours","volume":"18","author":"Teunissen","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib87","first-page":"292","article-title":"Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors","volume":"23","author":"Delpassand","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib88","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib89","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib90","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.beem.2007.01.007","article-title":"Neuroendocrine tumors","volume":"21","author":"Forrer","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib91","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","article-title":"Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study","volume":"21","author":"Cwikla","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib92","doi-asserted-by":"crossref","unstructured":"Toumpanakis C, Quigley A, Srirajaskanthan R, et al. 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. Paper presented at: American Society of Clinical Oncology 2009, 29 May\u20132 June; Orlando, FL.","DOI":"10.1200\/jco.2009.27.15_suppl.4594"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib93","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib94","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12094-009-0310-5","article-title":"Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues","volume":"11","author":"Muros","year":"2009","journal-title":"Clin Transl Oncol"},{"issue":"4 Suppl","key":"10.1053\/j.seminoncol.2012.11.006_bib96","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.24796","article-title":"177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy","volume":"116","author":"Garkavij","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib97","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib98","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00259-007-0688-7","article-title":"Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours","volume":"35","author":"van Essen","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib99","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2011.37.2151","article-title":"Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers","volume":"30","author":"Villard","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.11.006_bib100","first-page":"13S","article-title":"Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs","volume":"46","author":"de Jong","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib101","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bpg.2005.04.001","article-title":"Endocrine tumours of the gastrointestinal tract","volume":"19","author":"Teunissen","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1053\/j.seminoncol.2012.11.006_bib102","doi-asserted-by":"crossref","first-page":"e34019","DOI":"10.1371\/journal.pone.0034019","article-title":"PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose","volume":"7","author":"Arora","year":"2012","journal-title":"PLoS One"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412002059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412002059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:54:31Z","timestamp":1758804871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775412002059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0093775412002059"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.006","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}